Rezolute, Inc. - 8-K Filing

FDA recommends a pre-BLA meeting for ersodetug in congenital HI following sunRIZE trial data review (Items: 7.01 Regulation FD Disclosure)

SEC EDGAR ·

Tickers: $RZLT

Read the full article at SEC EDGAR

More Regulatory news